Related Experiment Videos
Intermittent androgen suppression in patients with prostate cancer
A De La Taille1, M Zerbib, S Conquy
1Department of Urology, CHU Cochin, Paris, France. ad399@hotmail.com
BJU International
|March 5, 2003
Summary
Intermittent androgen suppression (IAS) is a feasible prostate cancer treatment. Younger patients with higher Gleason scores and PSA levels are more prone to biochemical progression.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer management often involves androgen-deprivation therapy (ADT).
- Intermittent androgen suppression (IAS) offers an alternative treatment schedule for prostate cancer.
- Predicting biochemical progression is crucial for optimizing IAS treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of intermittent androgen suppression (IAS) in prostate cancer patients.
- To identify predictive factors for biochemical progression during IAS treatment.
Main Methods:
- 146 prostate cancer patients received IAS between 1989 and 2001.
- Treatment involved cycles of ADT followed by treatment breaks based on PSA levels.
- Patients had localized, advanced, or metastatic prostate cancer, or PSA recurrence post-treatment.
Main Results:
- 24 patients experienced biochemical progression after a mean follow-up of 45.6 months.
- Younger age (<70 years), higher Gleason score (≥8), higher PSA levels, and shorter treatment-free intervals predicted progression.
- Five-year metastatic disease-free survival was 91.3%, and biochemical recurrence-free survival was 68%.
Conclusions:
- IAS is a feasible treatment option for prostate cancer.
- Optimal candidates for IAS are older patients (>70 years) with localized prostate cancer and Gleason score ≤7.
- Identifying predictive factors aids in patient selection and treatment monitoring.